Kornimate/medical-research-clean huggingface dataset:
quality of life after thyroidectomy (thyrqol)

Conditions: Total Thyroidectomy

Summary: the purpose of this study is to evaluate the evolution of quality of life and voice function with different questionnaires (vih, sf36) before and after total thyroidectomy.


Eligibility criteria:
inclusion criteria: * adult over 18 years * notice to total thyroidectomy * thyroidectomy under cervicotomy or videoscopy * existence of a written informed consent of the patient * affiliation to a social security * possible follow-up for 6 months exclusion criteria: * impossibility for the patient to complete the forms * impossibility to follow the patient patient with serious disease which impact the quality of life * medullary thyroid cancers * preoperative examination of vocal cords (if performed) finding a violation of the vocal cords * lack of monitoring possible during the 6 months after surgery * pregnant women or during lactation * minors and adults under guardianship

Keywords: quality of life-thyroidectomy-morbidity
addressing unintentional leakage when using nasal cpap - study b

Conditions: Continuous Positive Airway Pressure; Adverse Effect; Obstructive Sleep Apnea

Summary: oral unintentional leak is a common side effect of continuous positive airway pressure (cpap) for obstructive sleep apnea (osa) treatment. management of oral unintentional leakage has not been standardized and the effectiveness of potential approaches have not been studied in controlled studies. higher levels of cpap are associated with higher leak. in the present study, a sequential approach to control excessive unintentional leak will be tested. in study a, the reduction of therapeutic cpap level will be tested. in study b, oronasal cpap will be compared to nasal cpap with a chinstrap.

study b will consist of a controlled crossover trial to compare unintentional leak during the use of an oronasal mask versus a nasal mask with a chinstrap, among subjects who remain with excessive leak at the end of study a. the order of interventions will be randomized. one of the groups will initially use an oronasal mask for 10 days. a washout period of 7 days under nasal cpap will follow. after washout, subjects will continue using a nasal mask and will be asked to use a chinstrap for another 10 days. in the other group, the order of interventions will be the opposite.

Eligibility criteria:
inclusion criteria: * diagnosis of moderate and severe obstructive sleep apnea; * use of cpap with a nasal mask; * 95th percentile of unintentional leak from the last 7 days above 24 l/min, or at least 4 sudden drops of leak over one night of nasal cpap * persistence of excessive leak at the end of study a. exclusion criteria: * patients who experience unintentional leakage from the mask/accessories. * diagnostic polysomnography examination with a predominance of central apnea; * patients with unstable heart disease, bedridden, neurodegenerative diseases, severe psychiatric disorders and copd; * previous surgery for obstructive sleep apnea; * severe nasal obstruction (nose questionnaire score equal or greater then 55 points).

Keywords: cpap excessive leak obstructive sleep apnea
effect of induced trunk extensors fatigue on balance and lumbar position sense in adolescents

Conditions: Healthy; Adolescent

Summary: this study will be conducted to investigate the effect of trunk extensors induced fatigue on balance and lumber position sense in adolescents

fatigue can be defined as, decrease in the power generation capacity of the muscles from the beginning of the movement due to internal homeostasis breakdown caused by an increase in energy production demanded by an external stimulus that lead to general decrease in physical performance related to a rise within the real/perceived difficulty of a task or exercise, as well as the inability of the muscles to keep up with the specified level of strength during exercises. either adolescents spending long time using smartphone, they are more likely to have their spine in an incorrect posture causing damage to the surrounding skeletal structures as well as to ligaments which affect the proprioception input of the spine. muscle fatigue is an important condition that impairs sensorimotor integration, proprioception, and thus postural control. muscle fibers and golgi tendon organ activity decrease with fatigue, resulting in changes in joint proprioception and afferent output from joint and muscle receptors. fatigue of postural muscles such as lumbar extensor and abdominal muscles impairs postural control and may form the basis for injuries. fatigue can also impair the proprioceptive and kinesthetic properties of the joints. this study aims to investigate how the trunk extensor muscles respond to a fatigue inducing exercise, especially concerning balance and trunk lumbar position sense for understanding and preventing musculoskeletal injury and lowering risk in health adolescents in primary care and to contribute to preventive rehabilitation. sixty-eight normal adolescent boys will participate in this study

Eligibility criteria:
inclusion criteria: * only boys will be included. * their age will range from 16 to 18 years old. * never trained any specific sport before. * they have a normal body mass index (bmi) between 16.4 to 24.8 kg/m2 according to * no history of low back (pain intensity 0-1 cm) according to 10 cm visual analog scale (vas) * physical fitness of all participants will be (minimally active) according to international physical activity questionnaire- short form (ipaq-sf) exclusion criteria: * visual or hearing defects. * congenital abnormalities. * musculoskeletal abnormalities. * recent trauma. * cardiac and respiratory problems. * smoker participant. * low back pain.

Keywords: induced trunk extensor fatigue balance lumbar position sense
intracoronary human wharton's jelly- derived mesenchymal stem cells (wj-mscs) transfer in patients with acute myocardial infarction (ami)

Conditions: ST-Elevation Myocardial Infarction

Summary: the purpose of this study is to investigate the safety and efficacy of intracoronary human umbilical wharton's jelly-derived mesenchymal stem cell (wj-msc) transfer in patients with st-segment elevation acute myocardial infarction.

it has been demonstrated that mscs have the potential to differentiate into cardiomyocytes both in vitro and in vivo. several clinical trials have been performed using autologous bone marrow-derived mscs, but the results of these trials have been unsatisfactory because of a low number of mscs in older patients and in those with coronary heart disease. wj-mscs from the human umbilical cord matrix which are of epiblastic origin and contain both human embryonic stem cell (hesc) and human mesenchymal stem cell markers appear to have a number of important advantages: they do not raise ethical issues, are widely multipotent, are not tumorigenic, and are not immunogenetic. because of a short population doubling time they can be rapidly scaled up in large numbers. we performed a double-blind, placebo-controlled, multicenter trial, randomly assigning 160 patients with acute st-segment elevation myocardial infarction to receive an intracoronary infusion of wj-mscs or placebo medium into the infarct artery 4-7 days after successful reperfusion therapy.

Eligibility criteria:
inclusion criteria: 1. patients at least 18 years of age； 2. patients with 1st acute st-elevation myocardial infarction (ami) who undergo successful primary percutaneous coronary intervention (pci) thrombolysis in myocardial infarction (timi) flow grade 3, but have a substantial residual left ventricular regional wall-motion abnormality measured by 2-d echocardiography. 3. no contraindications to undergoing cell-therapy procedure within 1 weeks after ami and pci. 4. hemodynamic stability-defined as no requirement for intra-aortic balloon pump or for inotropic or blood-pressure supporting medications. 5. consent to protocol and agree to comply with all follow-up visits and studies. exclusion criteria: 1. presence of cardiogenic shock ( defined as systolic blood pressure \< 80 mmhg requiring intravenous pressors or intra-aortic balloon counterpulsation); 2. major bleeding requiring blood transfusion after acute reperfusion treatment; 3. a history of leucopenia; 4. thrombocytopenia; 5. hepatic or renal dysfunction; 6. evidence for malignant diseases; 7. unwillingness to participate;

Keywords: stem cell acute st-elevation myocardial infarction
magnetic-controlled capsule endoscopy vs. gastroscopy for detection of gastric diseases

Conditions: Gastric Diseases,; Gastric Ulcer,; Gastric Polyps,; Early Gastric Cancer,; Chronic Gastritis

Summary: a new magnetic-controlled capsule endoscopy (mce) was developed by ankon and got sfda's approval in china in 2013. it has recently been evaluated to compare the diagnostic accuracy of mce with that of standard gastroscopy for gastric diseases in 70 patients with encouraging results (in press). to further testify the diagnostic accuracy of mce for both the diffuse and focal diseases in stomach, we performed this single-blinded multi-center prospective study compared mce with gastroscopy in patients with gastric symptoms and indication for upper gi endoscopy.


Eligibility criteria:
inclusion criteria: * patients presented with gastric symptoms and ready for the first upper gi endoscopy * patients with known focal gastric diseases: gastric ulcer, gastric polyps, early gastric cancer, gastric stromal tumors and so on. * age of 18 years to 70 years exclusion criteria: * patients with impaired bowel movement from ileus or organic digestive diseases * patients with known large and obstructing tumors of the upper gi tract * patients after upper gi surgery or abdominal surgery altering gi anatomy * patients under full anticoagulation * patient in poor general condition * patients using equipment that may be affected by radio transmission * patients using equipment that may be affected by magnetic field * pregnancy or suspected pregnancy
controlling hyperadrenergic activity in neurologic injury

Conditions: Traumatic Brain Injury; Dysautonomia

Summary: traumatic brain injury (tbi) is frequently associated with a hyperadrenergic state accompanied by elevated levels of plasma catecholamines. in its more severe presentation, the hyperadrenergic state presents as dysautonomia, which is characterized by paroxysmal alteration in vital signs, including tachycardia. the investigators hypothesize that intravenous (iv) esmolol is as effective at controlling heart rate in hyperadrenergic states as oral propranolol, which is the standard of care. our primary endpoint is efficacy of iv esmolol vs a prn regimen of intermittent b-blockade in controlling heart rate below a pre-specified level (\< 100 bpm) after traumatic brain injury (tbi) or hemorrhagic neurologic injury. heart rates will be recorded continuously as well as hourly.


Eligibility criteria:
inclusion criteria: * tbi (moderate/severe tbi (gcs 12 or head ais\>1) or hemorrhagic neurologic injury * hyperadrenergic activity: at least one paroxysmal episode (lasting at least 15 minutes) of heart rate 110 beats per minute during two or more consecutive days plus at least two more of the following that may not be better explained by another disease process (ex: sepsis): temperature of 38.5c respiratory rate 20 breaths per minute agitation diaphoresis dystonia stimulus responsive ("triggering of paroxysm") - informed consent obtained exclusion criteria: * patients that do not meet criteria for dysautonomia (as stated above) * age \<18 years * pregnancy * hypotension - requiring pressor therapy to maintain baseline adequate cpp or mean arterial pressure * cardiac arrhythmia - sinus bradycardia (hr \<60), 2nd or 3rd degree av block * hemodynamic contraindications to intravenous beta-blockade such as a documented history of congestive heart failure (chf), dependency on cardiac inotropes or documented bronchospastic disease * any patient on chronic beta blockade as an outpatient. * life expectancy \< 48 hours or patients with "do not resuscitate orders" * ongoing seizure activity * informed consent not obtained

Keywords: traumatic brain injury dysautonomia brain injury sympathetic hyperactivity
a phase i study of cyc140, a plk-1 inhibitor, in advanced leukemias or mds

Conditions: AML, Adult; Myelodysplastic Syndromes; ALL, Adult; CML, Refractory; CLL, Refractory

Summary: a phase i pharmacologic study of cyc140, a polo-like kinase 1 inhibitor, in patients with advanced leukemias or myelodysplastic syndromes

this is a first in human, open-label, single arm, dose escalation study in patients with advanced leukemias or myelodysplastic syndromes. patients will receive cyc140 as a 1 hr infusion once a week for 2 weeks followed by 1 week of rest on an outpatient basis. one treatment cycle is 3 weeks.

Eligibility criteria:
inclusion criteria: * diagnosis of relapsed or refractory advanced leukemias or mds * ecog 0-2 * adequate renal function * adequate liver function * ≥ 2 weeks from prior chemotherapy, radiation therapy or major surgery * ≥ 4 weeks from other investigational anticancer therapy * agree to practice effective contraception exclusion criteria: * known cns involvement by leukemia * currently receiving radiotherapy, biological therapy, or any other investigational agents * uncontrolled intercurrent illness * pregnant or lactating * known to be hiv-positive * known active hepatitis b and/ or hepatitis c infection

Keywords: aml, all, cll, cml, mds, advanced leukemias, leukemia
alternatives to manage dental fear

Conditions: Fear Anxiety; Discomfort; Psychotherapy Intervention Evaluation

Summary: this study compares the psychological effects on patients attend the dental clinic by listening to specific audios

participants of the experimental group listened to quran recitation using auto-controlled headphones, whereas headphones of the control group participants were silent then the two groups answer questionnaire prepared for this purpose.

Eligibility criteria:
inclusion criteria: * any patient eligible for dental treatment * willing to participate exclusion criteria: participants * less than 18 years of age, * mentally retarded, * had hearing impairment or deafness

Keywords: quran fear discomfort dentistry
mid-term natural course postoperative of crowe type iii-iv hip dysplasia

Conditions: Hip Arthropathy; Hip Dysplasia

Summary: comparison of preoperative and postoperative mid-term course of patients with crowe type 3 and type 4 hip dysplasia.

crowe type 3 and type 4 patients who underwent shortened hip replacement surgery will be followed up for 2 years. patients will be called for routine outpatient controls at the 2nd week, 6th week, 3rd month, 6th month, 12th month, 24th month. patients will be referred to the physical therapy specialist for abduction strengthening and pelvis tilt corrective exercises starting from the 6th week. scoliosis and orthoroentgenography x-rays will be taken at the last control of the patients. hhs, womac hip score and sf-12 score will be obtained from the patients. scores, lower extremity and spine angles will be evaluated after the last examinations performed at 12 and 24 months.

Eligibility criteria:
inclusion criteria: * crowe type 3 and 4 patients over 18 years of age who had shortened hip replacement surgery exclusion criteria: * crowe type 1 or 2 patients over 18 years of age who had shortened hip replacement surgery * patients who have previously operated on the contralateral hip * patients who underwent shortened hip replacement for a reason other than developmental dysplasia of the hip
quality of life and life satisfaction in pediatric and adolescent gymnasts through injury

Conditions: Musculoskeletal Injury; Quality of Life

Summary: this study aims to assess the quality and life and life satisfaction of pediatric and adolescent gymnasts throughout their musculoskeletal injury recovery.


Eligibility criteria:
inclusion criteria: * male and female gymnasts ages 8-18 years old * participating in excel or developmental gymnastics programs who present to children's hospital colorado sports medicine or orthopedic clinics with a musculoskeletal injury. exclusion criteria: * gymnasts only participating in colorado association for recreational athletics (cara) gymnastics, retired gymnasts, and adult or collegiate gymnasts. * vulnerable populations (prisoners, pregnant women, individuals with decreased decision making capacity(

Keywords: gymnastics quality of life and life satisfaction
autologous blood for full-thickness macular hole

Conditions: Ophthalmopathy

Summary: autologous blood for primary and recurrent holes

utilizing whole autologous blood for closing both primary and recurrent holes. here, we apply a drop of the taken whole blood over the hole, and the access blood will be aspirated on the macula with a silicon-tipped active back-flash cannula, to abolish all the possibilities of the fibrinogenic behavior of the whole blood composition, which might cause traction and recurrent hole formation. therefore, only the hole will be filled with blood. the blood will be taken under completely sterile and aseptic conditions. the air infusion will be raised after the valve of one of the trocars will be removed, to allow the air current to dry the clot inside the hole rapidly. then air gas exchange will be performed to allow the clot to remain away from intraocular fluids for one to two weeks and abolish the possibility of the clot being dissolved.

Eligibility criteria:
inclusion criteria: * primary and recurrent holes exclusion criteria: * lamellar and pseudoholes

Keywords: full thickness macular hole blood clot whole blood pars-pana vitrectomy
her2 expression of her2 affibody-based pet/ct to predict response in bladder cancer patients treated with adc

Conditions: HER2 Positive or Suspicious Positive Tumors

Summary: to use the molecular pet radionuclide (f-18) labelled her2 affibody to evaluate the predictive and prognostic value of her2 expression in bladder cancer patients treated with her2 adc


Eligibility criteria:
inclusion criteria: 1. aged # 18 years old; ecog 0 or 1; 2. is unresectable or metastatic; 3. patients with her2 positive or suspicious positive tumors; 4. was previously treated with trastuzumab and taxane in the advanced setting or progressed within 6 months after neoadjuvant or adjuvant treatment involving a regimen including trastuzumab and taxane; 5. has adequate cardiac, bone marrow, renal, hepatic and blood clotting functions; 6. receives anti-her2 adc treatment 7. life expectancy \> 3 months exclusion criteria: 1. significant hepatic or renal dysfunction; 2. is pregnant or ready to pregnant; 3. cannot keep their states for half an hour; 4. refused to join the clinical research; 5. suffering from claustrophobia or other mental disorders; 6. any other situation that researchers considered it unsuitable to participate in the trial.
study to evaluate the 2-way interaction between multiple doses of epanova™ and a single dose of rosuvastatin (crestor®)

Conditions: Hypertriglyceridemia

Summary: this study is intended to evaluate the potential 2-way reciprocal interaction between multiple doses of epanova™ and a single dose of rosuvastatin

the pk of rosuvastatin will be monitored following single-dose administration of rosuvastatin with and without multiple-dose administration of 4 g epanova™ for 13 consecutive days in order to detect a possible interaction between rosuvastatin and epanova™. the pk of total epa, total dha and total epa+dha will also be monitored following multiple-dose administration of epanova™ with and without single-dose administration of 40 mg rosuvastatin. a single dose administration for rosuvastatin has been judged sufficient to yield plasma concentrations that will be detectable with an adequate validated analytical method and characterize adequately the pk of rosuvastatin.

Eligibility criteria:
inclusion criteria: * male or female (non-childbearing potential) * body mass index (bmi) ≥ 18.5 and ≤ 32.0 kg/m2 at screening * non-smoker * medically healthy with no clinically significant laboratory profiles, vital signs or ecgs exclusion criteria: * mentally or legally incapacitated or has significant emotional problems at the time of screening visit or expected during the conduct of the study * history or presence of myopathy and/or hypothyroidism. * history or presence of transaminase elevations * history or presence of hypersensitivity or idiosyncratic reaction to rosuvastatin, to other hmg-coa reductase inhibitors, to epanova™, to vascepa®, or to related compounds * known sensitivity or allergy to soybeans, fish, and/or shellfish. * has consumed fish within 7 days prior to check-in. * female subjects who are pregnant or lactating. * positive urine drug and alcohol results at screening or check-in. * positive urine cotinine at screening and check-in * use of any drugs known to be inducers of cyp enzymes and/or p-gp * donation of blood or significant blood loss within 56 days prior to the first dose of study medication. * plasma donation within 7 days prior to the first dose of study medication. * participation in another clinical trial within 28 days prior to the first dose of study medication.

Keywords: epanova omega-3 carboxylic acids vascepa eicosapentaenoic acid ethyl ester crestor rosuvastatin
extension study of iron chelation therapy with deferasirox in β-thalassemia and rare chronic anemia patients

Conditions: Anemia; Hemosiderosis

Summary: a 1-year randomized phase ii core trial was conducted to investigate the efficacy of deferasirox in regularly transfused patients with β-thalassemia and other rare chronic anemia 2 years of age and older. patients who successfully completed the main trial may continue in the extension trial to receive chelation therapy with deferasirox for up to 3 years. extension was prolonged to 4 years. the objective of this study is to assess the long-term safety and efficacy of deferasirox in these patient groups.


Eligibility criteria:
inclusion criteria: * patients completed the planned 12-month core study * female patients who have reached menarche and who are sexually active must use double-barrier contraception, oral contraceptive plus barrier contraceptive, or must have undergone clinically documented total hysterectomy and/or ovariectomy, or tubal ligation * written informed consent obtained from the patient and/or legal guardian on the patient's behalf in accordance with the national legislation exclusion criteria: * pregnant or breast feeding patients other protocol-defined inclusion/exclusion criteria may apply

Keywords: β-thalassemia rare chronic anemia iron overload deferasirox chronic anemias transfusional hemosiderosis